NEW YORK, May 31, 2017 /PRNewswire/ --
Focus on Stock-Callers.com this morning is on Kite Pharma Inc. (NASDAQ: KITE),Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Biotech is a highly volatile and unpredictable sector due to the scientifically intensive operations of companies
On Tuesday, shares in Santa Monica, California headquartered Kite Pharma Inc. recorded a trading volume of 619,792 shares. The stock ended the session 1.00% lower at $72.38. The Company's shares have gained 2.27% over the previous three months and 61.42% on an YTD basis. The stock is trading 20.26% above its 200-day moving average. Moreover, shares of Kite Pharma, which focuses on the development and commercialization of novel cancer immunotherapy products, have a Relative Strength Index (RSI) of 43.45.
On May 09th, 2017, research firm FBR & Co. reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $90 a share to $91 a share.
On May 26th, 2017, Kite Pharma announced that the US Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application for axicabtagene ciloleucel. The submission follows positive data demonstrated with a single infusion of axicabtagene ciloleucel in the ZUMA-1 Phase-2 trial in patients with refractory aggressive non-Hodgkin lymphoma. The FDA has set a Prescription Drug User Fee Act target action date of November 29th, 2017. The free research report on KITE is available at:
Pasadena, California headquartered Arrowhead Pharmaceuticals Inc.'s stock closed the day 2.60% lower at $1.50 with a total trading volume of 400,570 shares. The Company's shares are trading 10.91% below their 50-day moving average. Shares of the Company, which develops novel drugs to treat intractable diseases in the US, have an RSI of 32.90. The complimentary report on ARWR can be downloaded at:
Shares in Novato, California headquartered Ultragenyx Pharmaceutical Inc. recorded a trading volume of 324,699 shares. The stock ended yesterday's trading session 5.19% lower at $53.01 The Company's shares are trading below their 50-day moving average by 16.15%. Furthermore, shares of Ultragenyx Pharma, which focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the US, have an RSI of 30.94.
On May 23rd, 2017, Ultragenyx Pharmaceutical announced that a Biologics License Application submitted to the US FDA, and a Marketing Authorization Application submitted to the European Medicines Agency for recombinant human beta-glucuronidase, an investigational therapy for the treatment of Mucopolysaccharidosis VII, were accepted for review. The Prescription Drug User Fee Act goal date for a decision is November 16th, 2017, and an opinion from the Committee for Medicinal Products for Human Use is expected in the first half of 2018. Visit us today and download our complete research report on RARE for free at:
Dublin, Ireland headquartered Jazz Pharmaceuticals PLC's stock finished Tuesday's session 1.95% lower at $148.17 with a total trading volume of 403,955 shares. The Company's shares have advanced 11.73% over the previous three months and 35.90% since the start of this year. The stock is trading above its 200-day moving average by 15.46%. Additionally, shares of Jazz Pharma, which identifies, develops, and commercializes pharmaceutical products for various medical needs in the US, Europe, and internationally, have an RSI of 41.42.
On May 15th, 2017, research firm RBC Capital Markets initiated an 'Outperform' rating on the Company's stock, with a target price of $210 per share.
On May 24th, 2017, Jazz Pharma announced that 12 abstracts supporting its sleep medicine portfolio, including data on its investigational compound JZP-110, data on the investigational use of sodium oxybate for the treatment of cataplexy and excessive daytime sleepiness in pediatric patients with narcolepsy, and data from the Nexus narcolepsy patient registry, will be presented at the 31st Associated Professional Sleep Societies Annual SLEEP Meeting on June 03rd, 2017, to June 07th, 2017, in Boston, MA. Get free access to your technical report on JAZZ at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Craniosynostosis is a condition where the bones of the skull are fused together prematurely ...
Episiotomy is a surgical incision made in the perineum between the vaginal orifice and the anus ...
Stickler syndrome is a rare genetic disorder which causes multisystem disorders predominantly ...View All